Department of Nutrition, Medical School, Mashhad University of Medical Sciences, Mashhad, Iran.
Department of Anesthesiology, Mashhad University of Medical Sciences, Mashhad, Iran.
Syst Rev. 2021 Apr 2;10(1):95. doi: 10.1186/s13643-021-01633-5.
The objective of this systematic review was to evaluate the effect of pre-, pro-, and synbiotics on feeding tolerance of enterally fed critically ill adult patients.
MEDLINE, Science Direct, Web of Knowledge, and the Cochrane Central Register of Controlled Trials were searched up to November 2019. English language randomized controlled trials reporting the effect of pre, pro or synbiotics on the feeding tolerance of enterally fed critically ill adult patients were included.
Overall, 15 papers were selected for review. Among six studies reporting the energy intake, only two studies showed significantly higher energy intake in the prebiotic-receiving groups. Among four RCTs reporting frequency or time to achieve the target calorie, only one found a significant effect of probiotics to reduce the time to achieve a target dose of calorie. About the prevalence or duration of diarrhea, 7 out of 12 RCTs reported a beneficial effect. All but one study found no beneficial effects for gut microbiota manipulation on clinical endpoints including length of stay (LOS) in hospital and intensive care unit (ICU).
It should be noticed that the heterogeneity in study designs, product format, and ICU patient populations makes it difficult to draw any general conclusion. Overall, it seems that pre, pro, or synbiotics have no significant beneficial effect on feeding tolerance and clinical endpoints in critically ill adults, but they may reduce the prevalence or duration of diarrhea.
本系统评价的目的是评估预、生、合生制剂对接受肠内喂养的危重症成年患者喂养耐受性的影响。
检索 MEDLINE、Science Direct、Web of Knowledge 和 Cochrane 对照试验中心注册库,检索时间截至 2019 年 11 月。纳入报告预、生或合生制剂对接受肠内喂养的危重症成年患者喂养耐受性影响的英语随机对照试验。
共筛选出 15 篇论文进行综述。在报告能量摄入的 6 项研究中,仅有 2 项研究显示接受益生元的患者能量摄入明显更高。在报告频率或达到目标热量时间的 4 项 RCT 中,仅有 1 项发现益生菌对减少达到目标热量剂量的时间有显著影响。关于腹泻的发生率或持续时间,12 项 RCT 中有 7 项报告了有益的效果。除了 1 项研究外,所有研究均发现肠道微生物群操作对临床终点(包括住院和重症监护病房的住院时间)无有益影响。
应当注意的是,研究设计、产品形式和重症监护病房患者人群的异质性使得难以得出任何一般性结论。总体而言,预、生、合生制剂似乎对危重症成年人的喂养耐受性和临床终点没有显著的有益影响,但它们可能降低腹泻的发生率或持续时间。